Dysregulation of TrkB Receptors and BDNF function by amyloid-β peptide is mediated by calpain

Cerebral Cortex

Volumn 25, Issue 9, 2015, Pages 3107-3121

  Jerónimo Santos, André ^a,b   Vaz, Sandra Henriques ^a,b   Parreira, Sara ^a,b   Rapaz Lérias, Sofia ^a,b   Caetano, António P ^a,b   Scherrer, Valérie Buée ^c,d,e   Castrén, Eero ^f   Valente, Claudia A ^a,b   Blum, David ^c,d,e   Sebastião, Ana Maria ^a,b   Diógenes, Maria José ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c UNIV LILLE   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Alzheimer's disease; LTP; MDL28170; Neurodegeneration; Neurotrophins

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA TUBULIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR T1; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR T2; CALPAIN; CALPAIN 2; GLUTAMIC ACID; MESSENGER RNA; PHOSPHOLIPASE C GAMMA; PROTEIN SHC; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; BRAIN CORTEX; BRAIN SYNAPTOSOME; CONTROLLED STUDY; FEMALE; FETUS; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; HUMAN TISSUE; LONG TERM POTENTIATION; MALE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; CYTOLOGY; DRUG EFFECTS; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENETICS; MAMMALIAN EMBRYO; METABOLISM; NERVE CELL; PHYSIOLOGY; PREGNANCY; SPRAGUE DAWLEY RAT; SYNAPTOSOME; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALPAIN; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; FEMALE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; GLUTAMIC ACID; HUMANS; LONG-TERM POTENTIATION; MALE; NEURONS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, TRKB; SYNAPTOSOMES;

EID: 84973436844     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhu105     Document Type: Article

References (56)

1. Adamec E, Mohan P, Vonsattel JP, Nixon RA. 2002. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol. 104:92-104.
2. Albensi BC, Oliver DR, Toupin J, Odero G. 2007. Electrical stimulation protocols for hippocampal synaptic plasticity and neuronal hyper-excitability: are they effective or relevant? Exp Neurol. 204: 1-13.
3. Allen SJ, Wilcock GK, Dawbarn D. 1999. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun. 264:648-651.
4. Ancot F, Foveau B, Lefebvre J, Leroy C, Tulasne D. 2009. Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity. Oncogene. 28:2185-2195.
5. Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I, Maurice T, Tapia-Arancibia L. 2008. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis. 31:316-326.
6. Aroeira RI, Ribeiro JA, Sebastiao AM, Valente CA. 2011. Age-related changes of glycine receptor at the rat hippocampus: from the embryo to the adult. J Neurochem. 118:339-353.
7. Bak LK, Schousboe A, Waagepetersen HS. 2006. The glutamate/GABAglutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 98:641-653.
8. Bell KF, de Kort GJ, Steggerda S, Shigemoto R, Ribeiro-da-Silva A, Cuello AC. 2003. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett. 353:143-147.
9. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. 2009. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA. 106: 13594-13599.
10. Canas N, Pereira IT, Ribeiro JA, Sebastiao AM. 2004. Brain-derived neurotrophic factor facilitates glutamate and inhibits GABA release from hippocampal synaptosomes through different mechanisms. Brain Res. 1016:72-78.
11. Canas PM, Simoes AP, Rodrigues RJ, Cunha RA. 2014. Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer's disease. Neuropharmacology. 76 Pt A:51-56.
12. Chen G, Kolbeck R, Barde YA, Bonhoeffer T, Kossel A. 1999. Relative contribution of endogenous neurotrophins in hippocampal longterm potentiation. J Neurosci. 19:7983-7990.
13. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. 1997. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res. 49:71-81.
14. Cruz JC, Tsai LH. 2004. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med. 10:452-458.
15. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. 2003. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 40:471-483.
16. Devi L, Ohno M. 2012. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 37:434-444.
17. Diogenes MJ, Costenla AR, Lopes LV, Jeronimo-Santos A, Sousa VC, Fontinha BM, Ribeiro JA, Sebastiao AM. 2011. Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology. 36:1823-1836.
18. Dorsey SG, Renn CL, Carim-Todd L, Barrick CA, Bambrick L, Krueger BK, Ward CW, Tessarollo L. 2006. In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron. 51:21-28.
19. Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. 1996. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci. 16:3123-3129.
20. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, Tolosa E, Marti E. 1999. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 58:729-739.
21. Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. 1996. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 381:706-709.
22. Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. 2005. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 48:825-838.
23. Fontinha BM, Diogenes MJ, Ribeiro JA, Sebastiao AM. 2008. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology. 54:924-933.
24. Goll DE, Thompson VF, Li H, Wei W, Cong J. 2003. The calpain system. Physiol Rev. 83:731-801.
25. Gomes JR, Costa JT, Melo CV, Felizzi F, Monteiro P, Pinto MJ, Inacio AR, Wieloch T, Almeida RD, Graos M et al. 2012. Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. J Neurosci. 32:4610-4622.
26. Granic I, Nyakas C, Luiten PG, Eisel UL, Halmy LG, Gross G, Schoemaker H, Moller A, Nimmrich V. 2010. Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology. 59:334-342.
27. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA. 1997. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. 763:145-158.
28. Holscher C. 1998. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis. 5:129-141.
29. Holscher C. 2005. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci. 16:181-212.
30. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. 2000. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res. 76:347-354.
31. Kaplan DR, Miller FD. 2000. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 10:381-391.
32. Karran E, Mercken M, De Strooper B. 2011. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 10:698-712.
33. Kemppainen S, Rantamaki T, Jeronimo-Santos A, Lavasseur G, Autio H, Karpova N, Karkkainen E, Staven S, Miranda HV, Outeiro TF et al. 2012. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging. 33:1122 e1123-1139.
34. Klein R, Conway D, Parada LF, Barbacid M. 1990. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell. 61:647-656.
35. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. 1995. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA. 92:8856-8860.
36. Kubo T, Nishimura S, Kumagae Y, Kaneko I. 2002. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res. 70:474-483.
37. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 95: 6448-6453.
38. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. 2000. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:360-364.
39. Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, Moeller A, Green KN, LaFerla FM. 2012. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 181: 616-625.
40. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T et al. 2003. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38:555-565.
41. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:615-622.
42. Pfaffl MW 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
43. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. 1991. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 7:695-702.
44. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 64:253-265.
45. Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A. 2006. The therapeutic potential of the calpain family: new aspects. Drug Discov Today. 11:917-923.
46. Saito K, Elce JS, Hamos JE, Nixon RA. 1993. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA. 90:2628-2632.
47. Selkoe DJ 2002. Alzheimer's disease is a synaptic failure. Science. 298:789-791.
48. Smith JP, Lal V, Bowser D, Cappai R, Masters CL, Ciccotosto GD. 2009. Stimulus pattern dependence of the Alzheimer's disease amyloidbeta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. Brain Res. 1269:176-184.
49. Sousa VC, Assaife-Lopes N, Ribeiro JA, Pratt JA, Brett RR, Sebastiao AM. 2011. Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Delta9-tetrahy drocannabinol on spatial memory. Neuropsychopharmacology. 36:472-487.
50. Stoilov P, Castren E, Stamm S. 2002. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun. 290:1054-1065.
51. Tauszig-Delamasure S, Yu LY, Cabrera JR, Bouzas-Rodriguez J, Mermet-Bouvier C, Guix C, Bordeaux MC, Arumae U, Mehlen P. 2007. The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc Natl Acad Sci USA. 104:13361-13366.
52. Tong L, Balazs R, Thornton PL, Cotman CW. 2004. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci. 24:6799-6809.
53. Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA et al. 2008. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 118:2796-2807.
54. Vidaurre OG, Gascon S, Deogracias R, Sobrado M, Cuadrado E, Montaner J, Rodriguez-Pena A, Diaz-Guerra M. 2012. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 3:e256.
55. Wei Z, Song MS, MacTavish D, Jhamandas JH, Kar S. 2008. Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. Neuropharmacology. 54:721-733.
56. Wong J, Higgins M, Halliday G, Garner B. 2012. Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience. 210:363-374.